Professor Pan Shiyang, Jiangsu Provincial People's Hospital: There is a long way to go to detect circulating tumor cells

On November 13-14, 2020, the "2020 China POCT Annual Meeting" was held in Chongqing, hosted by the China Medical Device Industry Association's On-site Rapid Detection (POCT) Branch and the People's Government of Jiangbei District of Chongqing.
conference to "Beidou plus 5G, dream China POCT" as the slogan, to "precision anti-epidemic, health for all" as the theme, the forum covers on-site rapid detection applications, nanoenzyme and POCT, ultrasound detection, POCT and primary health care, POCT and six major centers and other topics, set up a theme conference, 13 academic sub-forum exchanges and enterprise product exhibition.
afternoon of the 13th, at the POCT marker conversion sub-forum, Professor Pan Shiyang, Director of the Department of Inspection of Jiangsu Provincial People's Hospital, gave a speech on the topic of "CTC separation and detection of existing technology", and the artery network made an editing of its wonderful views.
Pan Shiyang: Professor, Researcher, Chief Physician and Doctoral Mentor.
, Jiangsu Provincial People's Hospital, director of the Department of Inspection, Nanjing Medical University, department of medical examination.
also serves as vice chairman of the inspection medicine branch of the Chinese Medical Association, executive director of the inspection physician branch of the Chinese Physicians Association, and deputy director of the on-site rapid testing (POCT) branch of the China Medical Device Industry Association.
new molecular marker SP70 for the diagnosis and treatment of tumors such as non-small cell lung cancer (NSCLC), 9 national invention patents and 3 international invention patents have been granted.
based on its patented research results, a number of innovative detection and diagnostic techniques, including liquid biopsy, have been established and applied in clinical oncology diagnosis and treatment.
has presided over a number of provincial and national issues in the past five years.
,000-word academic giant "Clinical Molecular Diagnostics", published by people's health publishing house in 2013.
published more than 60 high-level academic papers by SCI and Medline.
traditional biopsy has many defects, can not detect the tumor development process of heterogeneity change tumor tissue has a large number of new blood vessels, tumor cells can destroy blood vessels, and then into the blood circulation.
in the early stages of tumor development, these cells are killed and removed by the immune system, so metastasis lesions cannot be formed in the distance.
as tumor cells grow locally, the ability to survive is becoming stronger and stronger due to changes in the heterogeneity of tumor cells, resulting in the emergence of new variants of tumor cells.
this time, some tumor cells have been able to avoid the immune system, by suppressing or avoiding cellular immunity, so that they can survive in the blood circulation for a long time.
circulating tumor cells (circulating tumor cells, CTC) refers to tumor cells that fall off from primary or metastasis tumors and enter the bloodstream.
Pan noted that traditional biopsies have many defects, such as a puncture of a tumor sample that can cause serious discomfort to the subject, a clinical risk of puncture, and an inconvenient puncture at some tumor anatomy locations.
of these defects is that tissue biopsies fail to assess the timing and spatial heterogeneity of tumors.
because tumor cells continue to produce new mutations like bacteria, creating new tumor cell populations.
after early tumor surgery, if there is a recurrence, it is difficult for the tumor samples originally diagnosed to represent the newly emerging tumor foyers that follow.
will face greater difficulty and the same risk if you perform another biopsy at this time.
CTC detection can continuously dynamically monitor and evaluate tumor progression stage CTC detection as a potential tumor biopsy alternative, by detecting tumor cells that fall off solid tumors and enter the blood circulation, the diagnosis of metastatic cancer is highly specific, can identify all types of tumor cells, and can further carry out molecular biology and genetic analysis of tumors.
, CTCs are non-invasive and can be continuously dynamically monitored to assess the stages of tumor progression compared to biopsies.
has shown that CTC can be used to assess tumor heterogeneity and mutation status.
, CTC testing is a very important tool in the clinical treatment of tumors.
the concentration of CTCs in the outer blood is very low, the concentration of tumor cells is particularly important.
Generally, there are two ways to collect tumor cells: one is to identify and collect them based on biomarkers on the surface of the tumor cells, and the other is to identify and collect them based on physical properties such as the size, specific gravity, density, and charge of the surface of the tumor cells.
, although various new CTC testing techniques have been used in clinical practice, but because of the low levels of CTC in the outer blood, as well as the presence of heterogeneity and so on, so far in addition to the 2004 U.S. Food and Drug Administration (FAD) approved CellSearch? There is no better CTC detection system based on new tumor markers.
, however, the detection system has not been well promoted and applied on a global scale because of the great defects in the target of the rich CTC chosen.
Cellsearch uses antigens from the source of the cortectal cells: the skin adhesion molecule (EpCAM) rich CTCs.
Although 95% of solid tumors originate in the epithel, they occur after cell carcinoma and in epithelocytosis (EMT) that occurs in the blood, at which point cells in CTC express low or no EpCAM.
Because the markers used are not specific to tumor cells and are low or non-expressive in tumor cells, they are less efficient and often lead to false negative or severely low test results.
, the discovery of new tumor-specific markers and their conversion in CTC detection are extremely important for CTC clinical testing.
marker SP70 has great potential in the prognosm prediction of malignant tumors such as lung cancer is a common malignant tumor.
lung cancer had the highest morbidity and mortality rate among male patients, and lung cancer had the second highest incidence (second only to breast cancer) among female patients and the highest mortality rate among female patients.
currently, the five-year survival rate for lung cancer patients is less than 15%.
, non-small cell lung cancer accounted for 80% to 85% of the total number of lung cancer patients.
pan says the low five-year survival rate for lung cancer is largely due to the lack of effective early screening and early diagnosis of lung cancer.
CTC test offers a 30s thieves of hope for early screening in lung cancer patients.
Pan notes that his team has discovered a protein tumor marker, SP70, which has high expression in non-small cell lung cancer and other types of malignant tumor plasma and on cell membranes, regulating more than 1,000 gene expressions downstream.
SP70 is a key protein that promotes the proliferation and invasive metastasis of tumor cells.
Team named the monoclonal antibody corresponding to the marker (antigen) NJ001.
the discovery of the SP70 markers can achieve cTC-specific richness, not only for cytological diagnosis, but also for NGS detection, the resulting DNA can be used for NGS detection, the detection effect is significantly better than ctDNA.
addition, through clinical studies, Professor Pan's team found that if tumor patients SP70 high expression, a considerable number of early lung cancer surgical removal patients died within 3 years due to tumor recurrence.
, the detection of this marker has great potential in the prognosm prediction of malignant tumors such as lung cancer.
, SP70 kits are currently certified in the European Union, and in October 2018, Serum SP70 ELISA test kits were approved by the National CFDA For Innovation Special.
CTC detection technology based on the new tumor marker SP70 will soon be applied to the clinic.
CTC testing is growing fast, but before it can truly enter a wide range of clinical applications, there is still a long way to go before more efforts are made to study new tumor markers.
Chen Xuanhua Source: Arterial Network Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Metz Medical and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here